ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)

PRESS RELEASE

published on 09/24/2025 at 08:00, 7 months 15 days ago

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
OSE Immunotherapeutics corrects material error in total number of shares and voting rights, refutes accusations, and provides clarity on shareholder agreements and proxy advisory recommendations

Correction Proxy Advisory Shareholder Agreements OSE Immunotherapeutics Material Error
BRIEF

published on 09/23/2025 at 22:35, 7 months 15 days ago

OSE Immunotherapeutics Responds to Court Decision

General Meeting Shareholder Rights OSE Immunotherapeutics Nantes Commercial Court Voting Rights Error
BRIEF

published on 09/23/2025 at 22:35, 7 months 15 days ago

OSE Immunotherapeutics répond à la décision du tribunal

Assemblée Générale Droits Des Actionnaires OSE Immunotherapeutics Tribunal De Commerce De Nantes Erreur Relative Aux Droits De Vote
PRESS RELEASE

published on 09/23/2025 at 22:30, 7 months 15 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
PRESS RELEASE

published on 09/23/2025 at 22:30, 7 months 15 days ago

OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes rejetant ses demandes. Erreur matérielle identifiée dans le calcul des droits de vote. Préparation de l'Assemblée Générale le 30 septembre 2025

Biotechnologie Assemblée Générale Tribunal De Commerce OSE Immunotherapeutics Décision
BRIEF

published on 08/29/2025 at 08:05, 8 months 11 days ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
BRIEF

published on 08/29/2025 at 08:05, 8 months 11 days ago

OSE Immunotherapeutics clarifie sa stratégie face à l'activisme des actionnaires

Priorités Stratégiques OSE Immunotherapeutics Activisme Des Actionnaires Procédures Judiciaires Tedopi® Et Lusvertikimab
PRESS RELEASE

published on 08/29/2025 at 08:00, 8 months 11 days ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 8 months 15 days ago

OSE Immunotherapeutics : Nouvelle Gouvernance et Objectifs Stratégiques

Stratégie Gouvernance Actionnaires Biotechnologie Tedopi Et Lusvertikimab
BRIEF

published on 08/25/2025 at 07:05, 8 months 15 days ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab

Published on 05/09/2026 at 01:55, 17 hours 18 minutes ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 17 hours 33 minutes ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 17 hours 43 minutes ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 19 hours 13 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 20 hours 12 minutes ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

Published on 05/09/2026 at 19:05, 8 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 22 hours 35 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 1 day ago

Designated Person Notification

View all EQS

Published on 05/07/2026 at 19:15, 1 day 23 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 23 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE

News